Not Yet Recruiting
Study to Characterise Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety of Anifrolumab Administered Subcutaneously (SC) or Intravenously (IV)
NCT07688980
- Conditions
- Autoimmune Diseases, Connective Tissue Diseases, Immune System Diseases, +3 more
- Locations
-
Not specified